Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paclitaxel
Drug ID BADD_D01653
Description Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Indications and Usage Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Marketing Status approved; vet_approved
ATC Code L01CD01
DrugBank ID DB01229
KEGG ID D00491
MeSH ID D017239
PubChem ID 36314
TTD Drug ID D0C4RB
NDC Product Code 0703-3213; 52222-0001; 65129-1308; 68083-179; 69539-159; 62422-0004; 68001-516; 68083-178; 0703-4768; 68554-0061; 46708-622; 47781-595; 62332-621; 62332-622; 63323-763; 72205-063; 60505-6230; 62332-620; 72205-062; 0517-4300; 0703-3216; 0703-3218; 17359-3055; 63126-902; 69539-158; 72205-061; 17359-4056; 49452-4961; 51446-0110; 59651-605; 0703-4764; 51446-0120; 46708-620; 61703-342; 68083-180; 0703-3217; 17359-4040; 62422-0002; 69539-157; 70860-215; 42533-111; 54893-0007; 65129-2039; 69443-022; 16714-137; 68817-134; 70860-200; 17359-4055; 65892-002; 24979-710; 46708-621
UNII P88XT4IS4D
Synonyms Paclitaxel | Anzatax | NSC-125973 | NSC 125973 | NSC125973 | Taxol | Taxol A | Bris Taxol | Taxol, Bris | Paclitaxel, (4 alpha)-Isomer | Paxene | Praxel | 7-epi-Taxol | 7 epi Taxol | Onxol
Chemical Information
Molecular Formula C47H51NO14
CAS Registry Number 33069-62-4
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6) O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lipoedema14.08.04.0210.000168%Not Available
Lichenoid keratosis23.01.01.0040.000280%Not Available
Device related infection11.01.08.018; 08.07.01.005--
Infusion site extravasation12.07.05.008; 08.02.05.0070.000112%
Breath sounds abnormal13.15.01.008--Not Available
Angiodermatitis23.06.04.004; 24.03.02.0240.000112%Not Available
Infusion site thrombosis24.01.01.022; 12.07.05.007; 08.02.05.0060.000112%Not Available
Bone marrow failure01.03.03.0050.002574%
Loose tooth07.09.05.0090.000280%Not Available
Cardiovascular insufficiency02.11.01.011; 24.06.03.0050.000112%Not Available
Cytopenia01.03.03.0120.000526%Not Available
Acute interstitial pneumonitis22.01.02.0160.000280%Not Available
Liver injury09.01.07.022; 12.01.17.0120.000728%Not Available
Organising pneumonia22.01.02.0080.000224%Not Available
Adverse reaction08.06.01.0180.000929%Not Available
Congenital skin disorder23.07.04.013; 03.05.01.008--Not Available
Hypertransaminasaemia09.01.02.0050.001343%Not Available
Oropharyngeal discomfort07.05.05.008; 22.12.03.0150.000246%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Kounis syndrome24.04.04.020; 10.01.03.037; 02.02.02.0200.000112%Not Available
Acute kidney injury20.01.03.016--
Foetal growth restriction18.03.01.0020.000168%
Nail bed disorder23.02.05.017--Not Available
Respiratory tract oedema22.02.07.0130.000112%Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.000560%
Adrenocorticotropic hormone deficiency05.03.02.0050.000112%Not Available
Diffuse alopecia23.02.02.0070.000336%Not Available
Candida infection11.03.03.021--
Acute motor-sensory axonal neuropathy17.09.01.002; 11.07.01.014; 10.04.10.0110.000112%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000783%
The 24th Page    First    Pre   24 25 26 27    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene